US0008991046 - Common Stock
3.54 -0.05 (-1.39%)
After market: 3.58 +0.04 (+1.13%)
ADMA BIOLOGICS INC
NASDAQ:ADMA (9/28/2023, 7:00:00 PM)After market: 3.58 +0.04 (+1.13%)
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The company is headquartered in Ramsey, New Jersey and currently employs 617 full-time employees. The company went IPO on 2013-10-17. The company develops, manufactures, and markets specialty plasma-derived biologics for the treatment and prevention of infectious diseases. The company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its patients include immune-compromised individuals who suffer from an underlying immune deficiency disorder and immune-suppressed for medical reasons. Its product includes BIVIGAM, an Intravenous Immune Globulin (IVIG) product indicated for the treatment of Primary Humoral Immunodeficiency (PI); ASCENIV an IVIG product indicated for the treatment of PI, and Nabi-HB which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen (HBsAg). Its ADMA BioCenters subsidiary operates over 10 source plasma collection facilities in the United States. Its Plasma Collection Centers segment provides a portion of its blood plasma for the manufacture of its products.
ADMA BIOLOGICS INC
C/O Adma Biologics, Inc., 465 State Route 17
Ramsey NEW JERSEY 07446
CEO: Adam S. Grossman
The company, which focuses on infectious diseases, reported its second-quarter earnings on Wednesday after the markets closed.
ADMA Biologics press release (ADMA): Q2 GAAP EPS of -$0.03 in-line.Revenue of $60.13M (+77.4% Y/Y) beats by $4.63M.FY2024 and 2025 Total Revenue Guidance Increased to $275...
2Q2023 Total Revenues of $60.1 Million, a 77% Y-o-Y Increase 2Q2023 Adjusted EBITDA(1) of $6.4 Million, a 160% Q-o-Q Improvement 2Q2023 Adjusted Net...
Conference Call Scheduled for August 9, 2023, at 4:30 p.m. ET
Here you can normally see the latest stock twits on ADMA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.